MEDIPOST has submitted an investigational new drug (IND) amendment to the US Food and Drug Administration (FDA) to initiate a Phase III trial of its cell therapy for knee osteoarthritis.
This amendment aims to advance MEDIPOST’s clinical programme for an umbilical cord blood-derived allogeneic mesenchymal stem cell therapy targeting symptomatic cartilage defects in knee osteoarthritis patients.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The planned Phase III study will enrol patients beginning in the first half of 2026.
Knee osteoarthritis continues to be a major source of pain and reduced mobility, highlighting the ongoing need for therapies that offer more than symptomatic relief.
The upcoming Phase III research will determine the role of regenerative cell therapy in addressing this unmet medical need.
MEDIPOST continues to build a portfolio of regenerative medicine products using its stem cell technology platform, focusing on scalable and off-the-shelf therapeutic methods.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataMEDIPOST CEO Edward Ahn said: “Submitting this IND amendment marks an important step toward advancing our US clinical programme. Knee osteoarthritis continues to place a significant burden on patients, with limited treatment options that address the underlying disease.
“Through this study, our focus is on generating rigorous clinical evidence that could support a new treatment approach for people living with this condition. Filing an IND amendment reflects our long-term commitment to advancing science that has the potential to make a meaningful difference for patients.”
In January 2026, MEDIPOST announced that its parent company had closed a $140m funding round led by Skylake Equity Partners and Crescendo Equity Partners, with participation from Korea’s growth equity fund.
The investment will support the expansion of scientific and operational capacities, infrastructure development, and scaling of manufacturing processes for the Phase III trial for knee osteoarthritis.
Cell & Gene therapy coverage on Clinical Trials Arena is supported by Cytiva.
Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
